Drug Trial Radar · NCT01146951
A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304)
Last checked: Nov 19, 2026Latest source record: Jan 24, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
66
Actual
Start
Jun 2010
Primary completion
Aug 2011
Study completion Aug 2011
Sponsor
- Lead sponsor
- Eisai LimitedEisai
- Sponsor type
- Industry
- First posted
- Jun 22, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 4 years, up to 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To confirm that the combination therapy of rufinamide has superior efficacy compared to placebo in patients with Lennox-Gastaut syndrome.
Conditions
- Lennox-Gastaut Syndrome
Interventions
Rufinamide (E2080)Drug
Rufinamide tablets administered orally twice daily after breakfast and dinner. Treatment was divided into a Dose Titration Period (2 weeks) and a Dose Maintenance Period (10 weeks). As a general rule, the dose was increased by 1 step every 2 days until it reached the target maintenance dose determined by body weight at the start of the Observation Period. Target maintenance dose: 15.0 - 30.0 kg: 1000 mg/day (5 tablets each in the morning and evening) 30.1 - 50.0 kg: 1800 mg/day (4 tablets in the morning and 5 in the evening) 50.1 - 70.0 kg: 2400 mg/day (6 tablets each in the morning and evening) \>= 70.1 kg: 3200 mg/day (8 tablets each in the morning and evening)
PlaceboDrug
Rufinamide Matching Placebo tablets administered orally twice daily after breakfast and dinner for a total of 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change in Tonic-Atonic Seizure Frequency From Baseline (Per 28 Days)Time frame: Baseline (28 day observational period) and End of Treatment (28 day treatment period)
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Nagoya, Aichi-ken, Japan
Site not named
Matsuyama, Ehime, Japan
Site not named
Fukuoka, Fukuoka, Japan
Site not named
Hiroshima, Hiroshima, Japan
Site not named
Sapporo, Hokkaido, Japan
Site not named
Kobe, Hyōgo, Japan
Site not named
Yokohama, Kanagawa, Japan
Site not named
Goshi-shi, Kumamoto, Japan
Site not named
Iwamuma-shi, Miyagi, Japan
Site not named
Omura-shi, Nagasaki, Japan
Site not named
Nara, Nara, Japan
Site not named
Niigata, Niigata, Japan
Site not named
Yufu-shi, Oita Prefecture, Japan
Site not named
Okayama, Okayama-ken, Japan
Site not named
Neyagawa, Osaka, Japan
Site not named
Osaka, Osaka, Japan
Site not named
Suita-shi, Osaka, Japan
Site not named
Moriya-shi, Shiga, Japan
Site not named
Shizuoka, Shizuoka, Japan
Site not named
Kodaira-shi, Tokyo, Japan
Site not named
Kokubunji-shi, Tokyo, Japan
Site not named
Shinjuku-ku, Tokyo, Japan
Site not named
Toyoma-shi, Toyama, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.